Kenvue Inc. (NYSE:KVUE) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC cut its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 58.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 238,410 shares of the company's stock after selling 335,387 shares during the quarter. Nisa Investment Advisors LLC's holdings in Kenvue were worth $5,717,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Continuum Advisory LLC raised its stake in Kenvue by 2,071.1% during the 1st quarter. Continuum Advisory LLC now owns 1,954 shares of the company's stock worth $47,000 after acquiring an additional 1,864 shares in the last quarter. Clarity Asset Management Inc. acquired a new stake in Kenvue during the 4th quarter worth $45,000. Rossby Financial LCC acquired a new stake in Kenvue during the 1st quarter worth $52,000. Golden State Wealth Management LLC raised its stake in Kenvue by 292.0% during the 1st quarter. Golden State Wealth Management LLC now owns 3,081 shares of the company's stock worth $74,000 after acquiring an additional 2,295 shares in the last quarter. Finally, Versant Capital Management Inc raised its stake in Kenvue by 77.9% during the 1st quarter. Versant Capital Management Inc now owns 3,415 shares of the company's stock worth $82,000 after acquiring an additional 1,495 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Performance

Shares of NYSE:KVUE traded up $0.43 during midday trading on Friday, hitting $21.35. The stock had a trading volume of 25,967,559 shares, compared to its average volume of 16,055,380. The company has a market capitalization of $40.96 billion, a PE ratio of 38.82, a P/E/G ratio of 3.25 and a beta of 0.83. The stock has a 50 day moving average price of $22.34 and a two-hundred day moving average price of $22.29. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63. Kenvue Inc. has a 1 year low of $17.85 and a 1 year high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.01. The business had revenue of $3.74 billion for the quarter, compared to the consensus estimate of $3.69 billion. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The business's quarterly revenue was down 3.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.28 earnings per share. As a group, equities analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were paid a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.84%. The ex-dividend date was Wednesday, May 14th. Kenvue's dividend payout ratio (DPR) is 149.09%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on KVUE shares. Evercore ISI started coverage on shares of Kenvue in a research note on Monday, March 24th. They set an "in-line" rating and a $25.00 price target on the stock. Citigroup reiterated a "neutral" rating on shares of Kenvue in a research note on Friday, June 13th. Redburn Atlantic assumed coverage on shares of Kenvue in a research note on Thursday, April 10th. They set a "neutral" rating and a $23.50 price target on the stock. Barclays raised their price objective on shares of Kenvue from $22.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Monday, May 12th. Finally, UBS Group raised their price objective on shares of Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Friday, May 9th. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $25.33.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.